September 25, 2015Thrombosis and Haemostasis
Bleeding events with dabigatran or warfarin in patients with venous thromboembolism
Why the study?
Does dabigatran reduce bleeding events compared to warfarin in patients with venous thromboembolism?
Population
5,107 patients with venous thromboembolism (pooled from RE-COVER and RE-COVER II trials)
Comparison
Dabigatran (treated for a mean of 164 days) vs Warfarin (treated for a mean of 164 days)
Design
Meta-analysis, double-dummy
Follow-up
mean 164 days
Authors
Discussion
Loading...
Member takes
Overview
Supports preferring dabigatran over warfarin to reduce bleeding in VTE; confirms pooled RCT evidence for NOAC use.
Structured PICO
Does dabigatran reduce bleeding events compared to warfarin in patients with venous thromboembolism?
P
Population
5,107 patients with venous thromboembolism (pooled from RE-COVER and RE-COVER II trials)
I
Intervention
Dabigatran (treated for a mean of 164 days)
C
Comparator
Warfarin (treated for a mean of 164 days)
O
Outcome
Incidence of any bleeding eventsafety
In patients with venous thromboembolism, dabigatran is associated with a significantly lower risk of bleeding compared to warfarin.
Cite This Study
Goldhaber et al. (2015) studied this question.